ERBB2 and neoplasm: In HER2+ amplified breast cancer cell lines, treatment with lapatinib induces an adaptive reprogramming of the kinome involving transcriptional upregulation of multiple tyrosine kinases including HER3, IGF1R, DDR1, MET, FGFRs and reactivation of HER2/HER3 signaling resulting in reactivation of AKT signaling, tumor cell survival, and proliferation (11, 47).